CS
PACB icon

Comerica Securities’s Pacific Biosciences PACB Stock Holding History

Comerica Securities’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-744
Closed -$6.09K – 1125
2022
Q4 		$6.09K Buy
+744
New +$6.41K ﹤0.01% 1094

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Comerica Securities's PACB Position: Q1 2023 in Review

Comerica Securities sold out of Pacific Biosciences (PACB) in Q1 2023, closing a stake of 744 shares — an estimated $6.09K sold.

Comerica Securities first reported a position in PACB in Q4 2022 and held it in 1 quarter. The position peaked at $6.09K in Q4 2022. 259 funds tracked by Wall St. Rank hold PACB as of Q1 2023.

  • Comerica Securities reported no remaining Pacific Biosciences position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 744 Pacific Biosciences shares in Q1 2023, an estimated $6.09K.
  • Comerica Securities first reported a position in Pacific Biosciences in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Pacific Biosciences position peaked at $6.09K in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.